Sponsor Dossier
Lundbeck
Sponsor Dossier for Lundbeck. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABILIFY
- Brand: BRINTELLIX
- Brand: CIPRAMIL
- Brand: CLOPIXOL
- Brand: EBIXA
- Brand: FLUANXOL
- Brand: LEXAPRO
- Brand: REXULTI
About
Lundbeck is an Australian Private Company with ABN 86070094290, based in New South Wales. The company is registered for GST and maintains an active entity status.
Portfolio
Lundbeck has 9 brands on the ARTG, of which 9 are indexable and 9 carry a Product Information document. 8 brands are PBS-listed, 6 have a PBAC outcome on record, and 4 have an AusPAR on record. Notable brands include ABILIFY, BRINTELLIX, CIPRAMIL, CLOPIXOL, EBIXA, FLUANXOL, LEXAPRO, REXULTI, VYEPTI.
Therapeutic focus
— Psychiatry: 6 brands — Neurology: 3 brands
PBS footprint
8 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-07-01, across 6 brands with a PBAC outcome on record. The latest AusPAR is 2022-03-03, across 4 brands with an AusPAR on record.